Experienced leadership driving BB Biotech

Dr. Thomas von Planta

Dr. Thomas von Planta is Chairman since 2024 and has been a member of the Board of Directors of BB Biotech AG since 2019. Since 2006, he is owner of CorFinAd AG – Corporate Finance Advisory (advisory for M&A transactions and capital market financings). He chaired the Bellevue Group from March 2015 until March 2019. Previously he worked for Vontobel Group from 2002 until 2006 as interim Head Investment Banking/Head of Corporate Finance and member of the extended executive board. Prior to that he was with Goldman Sachs from 1992 until 2002, lastly in London in the Equity Capital Markets Group/Investment Banking Division. Dr. von Planta holds a degree in law from the Universities of Basel and Geneva (Dr. iur.) and is also an attorney at law. Dr. von Planta has served as Chairman of the Board of Directors of Baloise Holding AG since April 2021 and, following the merger with Helvetia, as Chairman of the successor company Helvetia Baloise Holding AG since December 2025.

Prof. Dr. Mads Krogsgaard Thomsen

Prof. Dr. Mads Krogsgaard Thomsen is Vice-Chairman and has been on the Board of Directors of BB Biotech AG since 2020. In 2021, Prof. Dr. Thomsen became CEO of the Novo Nordisk Foundation. He was previously with Novo Nordisk where he served as Executive Vice President, Head of R&D and Chief Science Officer. Prof. Dr. Thomsen has chaired Danish Research Council programs within endocrinology, and he is a former president of Denmark’s National Academy of Technical Sciences. Until 2020, Prof. Dr. Thomsen chaired the governing board of the University of Copenhagen. He received his MD and PhD from the University of Copenhagen. He is a member of the Board of Directors of the BioInnovation Institute and a member of the Scientific Advisory Board of Felix Pharmaceuticals.

Laura Hamill

Laura Hamill has been a member of the Board of Directors of BB Biotech AG since March 2022. She brings more than 35 years of experience in the biopharma industry and most recently serviced as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences. Prior to Gilead, Ms. Hamill worked at Amgen for almost 20 years in a number of executive leadership roles in the United States (US) and internationally. In her last role at Amgen, she led the US Commercial Operations with annual revenue of USD 20bn. Ms. Hamill is a Director of Jazz Pharmaceuticals, Unchained Labs and consults with Launch Therapeutics, part of the Carlyle Group. Ms. Hamill holds a B.A. in Business Administration, with an emphasis in Marketing, from the University of Arizona.

Dr. Pearl Huang

Dr. Pearl Huang has been a member of the Board of Directors of BB Biotech AG since March 2022. Dr. Huang studied life sciences at MIT as an undergraduate and earned a doctorate in Molecular Biology from Princeton University. She has spent over 30 years in the pharma and biotech industries, and to date, has contributed to the development of nine medicines that are used by patients every day. Dr. Huang was appointed CEO of Dunad Therapeutics in June 2022. Prior to that she served as CEO of Cygnal Therapeutics as a Venture Partner at Flagship Pioneering. She is currently a member of the Board of Directors of Waters Corporation and a member of the advisory committee of MIT Corporation.

Camilla Soenderby

Camilla Soenderby has been a member of the Board of Directors of BB Biotech AG since March 2024. She brings 25 years of international leadership experience from executive roles at leading biopharma companies in the EU, the US and Asia. Most recently, Ms. Soenderby was a corporate officer at Takeda leading global portfolio commercialisation. Prior to that, she worked as SVP, Head of Global Product Strategy for Shire, having previously held regional- and general management positions at Roche Pharma, Abbott (now AbbVie) and Schering Plough (now Merck & Co). She began her career as a consultant at McKinsey & Company, and holds a Master’s degree from Copenhagen University. She is a Board Director at Abivax, F2G, member of the Novo Advisory Group and advisor to the private equity group EQT.

Dr. Christian Koch

Dr. Christian Koch, Head of the BB Biotech Team since 2025 and Executive Board Member of Bellevue Asset Management, joined Bellevue Asset Management in 2014 as a portfolio manager at BB Biotech. From 2013-2014 he was a sell-side Pharma & Biotech equity analyst at Bank am Bellevue in Küsnacht and from 2010-2013 a Research Associate at the Institute of Pharmaceutical Sciences at ETH Zurich. He holds a PhD in Computer-Assisted Drug Design from ETH Zurich and studied Bioinformatics from Goethe University Frankfurt.

Dr. Kyle Rasbach

Dr. Kyle Rasbach joined Bellevue Research Inc / New York in September 2025. Previously, he held senior positions at Eventide Asset Management, Pappas Capital, Lexeo Therapeutics, Zentalis Pharmaceuticals, and T. Rowe Price. He earned a PhD and PharmD in Pharmacology and Pharmacy from the Medical University of South Carolina and an MBA from The Citadel.

Dr. Maurizio Bernasconi

Dr. Maurizio Bernasconi joined Bellevue Asset Management as analyst and portfolio manager in 2017. Prior he was a sell-side equity analyst in the Pharma & Biotech department of Bank am Bellevue. Maurizio Bernansconi has a master's degree in chemistry at Swiss Federal Institute of Technology (ETH), Zurich, and has PhD in organic chemistry at the University of Basel.

Dr. Jordan Baumhardt

Dr. Jordan Baumhardt joined Bellevue Research Inc / New York in October 2025 as Investment Analyst. Prior to joining Bellevue, he held roles at Lexeo Therapeutics, Zentalis Pharmaceuticals, Eventide Asset Management, and LifeSci Capital. He holds a PhD in Pharmacology and Molecular Biophysics from the University of Texas Southwestern Medical Center and a BSc in Biochemistry and Molecular Biology from Illinois State University.

Dr. Anna Guinot Aguado

Dr. Anna Guinot Aguado joined Bellevue Asset Management in 2024. She previously worked at Nextech Invest, a European Biotech VC focused on oncology, where she gained investment experience in both private and public markets. Before her time at Nextech, Anna completed a PostDoc at the University Children's Hospital Zurich (Kispi) in the Oncology division and at the institute of physiology at the University of Zurich. She holds a PhD in Stem Cell & Cancer Biology from the University of Cambridge, after studying Biochemistry in Valencia and Molecular & Cell Biology in Paris.

Alex Arfaei

Alex Arfaei joined Bellevue Research Inc / New York in March 2026 as Investment Analyst. He previously held roles at Guidepoint, Pappas Capital, and BMO Capital Markets, among others. He brings over 15 years of experience across sell-side, buy-side, and venture capital. Alex holds an MBA from Duke University and a Bachelor of Science in Cell and Molecular Biology from the University of Toronto.

Sébastien Pires

Sébastien Pires has been Head of AI BB Biotech at Bellevue Asset Management since 2026, where he is responsible for the development and implementation of AI-driven solutions as well as leading related engineering initiatives. Prior to joining Bellevue, he served as VP Engineering at AllianceBernstein from 2023, where he developed AI-based applications to automate fundraising processes and trade reconciliation systems, and drove the modernization of system architecture and infrastructure. From 2019 to 2023, he was Technical Lead at Insig AI in London, where he developed core platforms and ESG analytics solutions. Previously, he worked as a Senior Software Engineer at Ryalto and Babylon Health, focusing on scalable platforms in the healthcare sector. He began his career as a Software Engineer at Sebia Group in London and as an IT Engineer at Solutys Group in Paris. Sébastien Pires holds a Master of Science in Computer Science from the University of Essex.

Dr. Olivia Woolley

Dr. Olivia Woolley joined Bellevue Asset Management in 2022. She is a member of the investment management team of BB Biotech. Previously she was associate director data science at Novartis, working in Technical Research and Development. Before entering industry she was a postdoctoral researcher at the Swiss Federal Institute of Technology (ETH), Zurich, in the area of digital epidemiology and complex networks. Olivia holds a PhD and MSc in Applied Mathematics from Northwestern University and a BSc in Mathematical and Computational Science from Stanford University.

Dr. Can Buldun-Gora

Dr. Can Buldun-Gora joined Bellevue Asset Management in 2022. From 2018 to 2022 he was a Computational Scientist at Roche Pharma Research & Early Development, focusing on data science and software solutions for next-generation antibody engineering. Can Buldun-Gora holds a PhD in Biochemistry from the University of Oxford and a BSc in Biochemistry & Cell Biology from Jacobs University Bremen.

Dr. Samuel Croset

Dr. Samuel Croset joined Bellevue Asset Management in 2020. He previously worked for Roivant Sciences from 2018-2020 as data scientist supporting investment decisions in drug projects as well as leading a team focused on the analysis of real-world data. Prior to that, he started his professional career at Roche as data scientist in the research department (2014-2018). Samuel holds a Ph.D. in Bioinformatics from the University of Cambridge, a MS in Bioinformatics and a MS in Biochemistry from the University of Geneva.

Xinya Guo

Xinya Guo is a Portfolio & Trading Specialist for BB Biotech at Bellevue Asset Management. Prior to this, she founded Bridge Quantamental Capital Management in 2025 and served as Chief Investment Officer, where she was responsible for the investment strategy of an equity long/short fund. From 2022 to 2024, she was Vice President and Multi-Asset Execution Trader at the Government of Singapore Investment Corporation (GIC) in London. Previously, she worked at HSBC, most recently as Associate Director in ETF & Delta One Trading, and earlier in CEEMEA Cash Equity Trading as well as a Prime Risk Analyst within Global Markets. Xinya Guo holds an MSc in Risk Management and Financial Engineering from Imperial College Business School and a BSc in Mathematics with Finance from the University of Liverpool.